Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Grifols S.A. (GRFS)

22.73   0.05 (0.22%) 12-12 16:00
Open: 22.69 Pre. Close: 22.68
High: 22.92 Low: 22.56
Volume: 1,116,321 Market Cap: 20612M
Grifols SA is a pharmaceutical company. It primarily collects the liquid portion of human blood called plasma and then manufactures and sells plasma-derived products globally. It also operates diagnostics, hospital supplies, and raw materials businesses.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 23.194 - 23.308 23.308 - 23.401
Low: 22.126 - 22.28 22.28 - 22.406
Close: 22.464 - 22.698 22.698 - 22.887

Technical analysis

as of: 2019-12-12 4:00:57 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 27.56     One year: 32.20
Support: Support1: 22.14    Support2: 21.24
Resistance: Resistance1: 23.60    Resistance2: 27.56
Pivot: 22.62
Moving Average: MA(5): 22.80     MA(20): 22.46
MA(100): 21.42     MA(250): 20.15
MACD: MACD(12,26): 0.33     Signal(9): 0.36
Stochastic oscillator: %K(14,3): 52.83     %D(3): 54.64
RSI: RSI(14): 59.05
52-week: High: 23.60  Low: 17.42  Change(%): 20.6
Average Vol(K): 3-Month: 116960  10-Days: 139876

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
GRFS has closed below upper band by 35.9%. Bollinger Bands are 29.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
BARCELONA, Dec. 12, 2019 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company's first 20%…

Global Blood Grouping Reagents Market 2020-2024 | Evolving Opportunities with DIAGAST and Grifols SA | Technavio
LONDON--(BUSINESS WIRE)-- #Biotechnology--Global blood grouping reagents market is poised to grow by USD 443.28 million during 2020-2024 at a CAGR of over 10% during the forecast period.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers - Major
Shares Out. (M) 684.13
Shares Float (M) 1050.00
% Held by Insiders
% Held by Institutions 60.84
Shares Short (K) 2490
Shares Short P. Month (K)

Stock Financials

EPS 0.600
Book Value (p.s.) 3.560
PEG Ratio 1.71
Profit Margin 11.12
Operating Margin
Return on Assets (ttm) 5.1
Return on Equity (ttm) 12.2
Qtrly Rev. Growth 14.9
Gross Profit (p.s.) 2.997
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth -8.60
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E 37.93
P/E Growth Ratio
P/BV 6.39

Dividends & Splits

Dividend 0.470
Dividend Yield 0.02
Dividend Pay Date 2019-12-11
Ex-Dividend Date 2019-12-02
Forward Dividend 0.440
Last Split Date 2016-01-04
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.